TSPO and Parkinson disease: Using [11C]-acetamide, N-((2-(methoxy−11C)-phenyl)methyl)-N-(6-phenoxy-3pyridinyl)acetamide ([11C]PBR28) as radioligands, a reduction of TSPO binding was reported in the striatum and SN of PD patients treated for 8 weeks with Verdiperstat, an orally active irreversible myeloperoxidase inhibitor (Jucaite et al., 2015).